Novel potent inhibitor of cyclin-dependent kinases (CDKs) 2, 5, and 9, displaying activities across more than 60 cancer cell lines

Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4

Novel inhibitor of the cyclin-dependent kinase 9 (CDK9)

Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity

Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel

Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel potent CDK8 inhibitor

Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition

Novel highly potent, selective, permeable CDK8 inhibitor

Novel inhibitor of CDK8

Novel potent and selective inhibitor of CDK8, also modulating CDK19

Potent dual inhibitor of CDK8/19, suppressing phosphorylated STAT1 in various cancer cells

Novel potent and selective dual inhibitor of CDK8 and CDK19

Novel potent CDK8 inhibitor

Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo

Novel potent CDK6 degrader

Potent, ATP-binding site-targeting Cdk4/D1 inhibitor

Novel potent and selective CDK12 inhibitor

Novel selective cdDHQD inhibitor

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel CD33 pre-mRNA splicing modulator, increasing exon 2 skipping in cellular mRNA pools

Novel CD22 glycan ligand, targeting CD22-expressing B cells, uptaking and enhancing siRNA gene expression knockdown via formation of CD22 glycan ligand-conjugated siRNA

Retinoic acid receptor beta (RARbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.

Novel telomerase inhibitor

Novel Caspase-1 inhibitor